Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Lyra Therapeutics Inc shares valued at $14,930 were purchased by Waksal Harlan on Apr 25 ’25. At $0.10 per share, Waksal Harlan acquired 145,370 shares.
Also, Palasis Maria purchased 39,567 shares, netting a total of over 3,545 in proceeds.
As published in a research note from Jefferies on May 07, 2024, Lyra Therapeutics Inc [LYRA] has been rated down from a Buy to a Hold and the price target has been revised to $0.50 from $10. Analysts at H.C. Wainwright downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early May. As of May 07, 2024, BofA Securities has decreased its “Buy” rating to a “an Underperform” for LYRA. Earlier on May 06, 2024, William Blair downgraded its rating. Their new recommendation was “a Mkt perform” for LYRA stock which previously was a “an Outperform”.
Analyzing LYRA Stock Performance
During the last five days, there has been a drop of approximately -11.62%. Over the course of the year, Lyra Therapeutics Inc shares have dropped approximately -49.13%. Shares of the company reached a 52-week high of $0.2286 on 01/02/25 and a 52-week low of $0.0820 on 04/09/25. A 50-day SMA is recorded $0.1371, while a 200-day SMA reached $0.2137.
Support And Resistance Levels for Lyra Therapeutics Inc (LYRA)
According to the 24-hour chart, there is a support level at 0.0886, which, if violated, would cause prices to drop to 0.0723. In the upper region, resistance lies at 0.1348. The next price resistance is at 0.1647. RSI (Relative Strength Index) is 44.61 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0014, which suggests the price will decrease in the coming days. Percent R is at 68.40%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
